On April 14, 2025, Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced the pricing of an underwritten public offering of shares of its common stock and accompanying common stock warrants and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants. The aggregate gross proceeds of the offering were approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses. Cue Biopharma also recently announced a strategic research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune disease.

The team representing Cue Biopharma for the public offering included Cynthia Mazareas, Caroline Dotolo, Erin Bruynell Gallagher and Joe Odegaard.